New hope for tough lung cancers: experimental combo challenges standard chemo
NCT ID NCT07464327
Summary
This study is for people with advanced non-squamous non-small cell lung cancer that has worsened after previous treatment. Researchers want to see if a new two-drug combination (HS-20093 plus adebrelimab) works better and is safer than the standard chemotherapy drug docetaxel. About 450 participants will be randomly assigned to receive either the experimental combination or the standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.